The comorbidities associated with schizophrenia take precious years from patients’ lives1,2

People living with schizophrenia die 10 to 20 years earlier than the general population.1,2
Because mental health clinicians logically focus much of their attention on the
psychiatric and behavioral aspects of treatment, there is often a delay in screening, detecting, and treating these devastating medical comorbidities.1


Common Medical Morbidities Among Patients With Schizophrenia1

87% 44% 29% 34% Cardiovascular Disease Metabolic Syndrome 51% 35% Obesity 45% 9% Diabetes US Adults US Adults With Schizophrenia

Cardiovascular disease (CVD) is by far the most common comorbidity in individuals with schizophrenia1,2

The root causes for CVD include smoking, obesity, hypertension, dyslipidemia, diabetes, and lack of physical activity—all of which are prevalent among patients with schizophrenia.3 Studies also show that patients with schizophrenia often have diets high in saturated fat, which increases their risk for developing metabolic complications.1,4 Adding to this risk is the fact that some antipsychotics are associated with metabolic effects, including weight gain, that can impact patients’ overall health.1

Patients with schizophrenia are at an increased risk for additional serious diseases compared to the general population.1


Premature Death Due to CVD6

SCZ Population | Age 20-59 General Population | Age 20-59 General Population | Age 60-79 SCZ Population | Age 60-79 Survival (%) 0 80 20 40 60 80 100 120 140 160 180 Time Since Diagnosisof Cardiovascular Disease (Days) 90 100

Cardiovascular disease (CVD) is the leading cause of early mortality in patients with schizophrenia1

Among the general US population, CVD was reported as the leading cause of death in 2018.5 This is also true for patients with schizophrenia but at a significantly higher rate. In fact, a 24-year national registry study of more than 10 million people with hospitalization due to CVD, including >46,000 with diagnosed schizophrenia, demonstrated that people with schizophrenia had 3x higher mortality from CVD than people in the general population. On top of that, CVD deaths occurred 10 years earlier in the same vulnerable population.6

Greater integration of physical and mental health care as part of any care plan is recommended for improving the management of CVD in people with schizophrenia.7


Risk of Mortality8

0 0.80 0.85 0.90 0.95 2 4 6 8 Years 1.00 Atypical-LAI Group Atypical-Oral Group Typical-Oral Group Typical-LAI Group Antipsychotics: No Use Survival Use of antipsychotic medication reduces the risk of death by 50% compared with no use8

Antipsychotics remain the cornerstone to improving survival8

Despite the well-documented negative impact that some antipsychotic formulations can have on lipids and glucose regulation, these medications remain pivotal for patients’ longevity. A 2018 prospective analysis of nearly 30,000 patients with schizophrenia demonstrated the beneficial net effect on mortality with the use of antipsychotic medication.8

Any care plan designed to improve overall patient health and well-being must begin with a careful selection of antipsychotic dose and formulation.8,9

Teva is committed to providing education and enhancing care for everyone living with schizophrenia.

The SCZ Now initiative was created to help support this educational effort.